The capital is pricing GLP-1 agonists as life-extension drugs for healthy adults. The trial endpoint is major adverse cardiovascular events in patients with established cardiovascular disease, 17,604 enrolled, 39.8 months of follow-up, hazard ratio 0.80 met, published in the New England Journal of Medicine, 2023. This was not an aging cohort. Singapore family-office health mandates have been moving into GLP-1 delivery infrastructure since late 2025 on the strength of that cardiovascular signal. No Phase 3 study of a GLP-1 agonist has used all-cause mortality in a non-diabetic, cardiovascularly healthy aging population as a primary endpoint. None has been filed.

TGA's Drug Evaluation Branch approved Ozempic (semaglutide 1mg) for type 2 diabetes management in 2020 and Wegovy (semaglutide 2.4mg) for weight management in adults with BMI at or above 30, or above 27 with a weight-related comorbidity, in 2023. NMPA's Center for Drug Evaluation approved semaglutide for glycaemic control in 2021. Neither has reviewed a longevity indication. No NDA for one exists. MOH Singapore's licensing framework for licensed medical practitioners permits off-label prescribing; the S$800-per-month private clinic is operating inside the rules. The endpoint is not registered. Eli Lilly's cardiovascular outcomes program for tirzepatide in adults with obesity but without established diabetes is expected to read primary data before December 2026; if it misses, GLP-1 longevity capital reprices against a regulatory record containing zero aging-indication approvals across TGA's Drug Evaluation Branch, NMPA's Center for Drug Evaluation, and PMDA.